EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Authors:
  • TBTitus J. Boggon
    Titus J. Boggon
  • TDTajhal Dayaram
    Tajhal Dayaram
  • PJPasi A. Jänne
    Pasi A. Jänne
  • OKOlivier Kocher
    Olivier Kocher
  • MMMatthew Meyerson
    Matthew Meyerson
  • BJBruce E. Johnson
    Bruce E. Johnson
  • MEMichael J. Eck
    Michael J. Eck
  • BHBalázs Halmos
    Balázs Halmos

Abstract
Mutations of the epidermal growth factor receptor (EGFR) gene have been identified in specimens from patients with non–small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors. Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse. The mechanism of the drug resistance is unknown. Here we report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non–small-cell lung cancer who had a relapse after two years of complete remission during treatment with gefitinib. The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR. Structural modeling and biochemical studies showed that this second mutation led to gefitinib resistance.

This publication has 23 references indexed in Scilit: